Retrospective database analysis of annual direct costs and complications for patients with type 1 diabetes and hypoglycemia in the US.

Adriana Boateng-Kuffour¹, Nanxin Li¹, Vamshi Ruthwik Anupindi², Keval Chandarana¹, Liang Chen¹, Michael Hull², Xiaoyu Zhou², Jason L Gaglia³, Mitch Dekoven², Beth Barber¹

¹Vertex Pharmaceuticals Incorporated, Boston, MA, USA.

²Real World Solutions, IQVIA, Falls Church, VA, USA.

³Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA.

PubMed DOI

Abstract

BACKGROUND: Type 1 diabetes and hypoglycemia impose substantial clinical and economic burden on patients and healthcare systems. This study examined T1D-related complications and direct costs in people with T1D (pwT1D) and in a subgroup with hypoglycemia in the US. METHODS: IQVIA's PharMetrics Plus database was used to identify adults (≥18 years) with an ICD-10-CM code for T1D between April 1, 20…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.